Antipsychotic drugs
Atypical antipsychotic agents |
| |
Recommended uses: control of problematic delusions, hallucinations, severe psychomotor agitation, and combativeness |
| |
General cautions: diminished risk of developing extrapyramidal symptoms and tardive dyskinesia compared with typical antipsychotic agents |
| |
Risperidone (Risperdal) |
Initial dosage: 0.25 mg per day at bedtime;maximum: 2 to 3 mg per day, usually twice daily in divided doses |
Comments: current research supports use of low dosages; extrapyramidal symptoms may occur at 2 mg per day. |
| |
Olanzapine (Zyprexa) |
Initial dosage: 2.5 mg per day at bedtime; maximum: 10 mg per day, usually twice dailyin divided doses |
Comments: generally well tolerated |
| |
Quetiapine (Seroquel) |
Initial dosage: 12.5 mg twice daily; maximum: 200 mg twice daily |
Comments: more sedating; beware of transient orthostasis. |
| Typical antipsychotic agents |
| |
Recommended uses: control of problematic delusions, hallucinations, severe psychomotor agitation, and combativeness; second-line therapy in patients who cannot tolerate or do not respond to atypical antipsychotic agents |
| |
General cautions: current research suggests that these drugs should be avoided if possible, because they are associated with significant, often severe side effects involving the cholinergic, cardiovascular, and extrapyramidal systems; there is also an inherent risk of irreversible tardive dyskinesia, which can develop in 50% of elderly patients after continuous use of typical antipsychotic agents for 2 years. |
| |
Haloperidol (Haldol), fluphenazine (Prolixin), thiothixene (Navane) |
Dosage: varies by agent |
Comments: anticipated extrapyramidal symptoms; if these symptoms occur, decrease dosage or switch to another agent; avoid use of benztropine (Cogentin) or trihexyphenidyl (Artane). |
| |
Trifluoperazine (Stelazine), molindone (Moban), perphenazine (Trilafon), loxapine (Loxitane) |
Dosage: varies by agent |
Comments: agents with "in-between" side effect profile |
|
Mood-stabilizing (antiagitation) drugs
|
| |
Recommended uses: control of problematic delusions, hallucinations, severe psychomotor agitation, and combativeness; useful alternatives to antipsychotic agents for control of severe agitated, repetitive, and combative behaviors |
| |
General cautions: see comments about specific agents. |
| |
Trazodone (Desyrel) |
Initial dosage: 25 mg per day; maximum: 200 to 400 mg per day in divided doses |
Comments: use with caution in patients with premature ventricular contractions. |
| |
Carbamazepine (Tegretol) |
Initial dosage: 100 mg twice daily; titrate totherapeutic blood level (4 to 8 mcg per mL) |
Comments: monitor complete blood cell count and liver enzyme levels regularly; carbamazepine has problematicside effects. |
| |
Divalproex sodium (Depakote) |
Initial dosage: 125 mg twice daily; titrate to therapeutic blood level (40 to 90 mcg per mL) |
Comments: generally better tolerated than other mood stabilizers; monitor liver enzyme levels; monitor platelets, prothrombin time, and partial thromboplastin time as indicated. |
|
Anxiolytic drugs
|
| Benzodiazepines |
| |
Recommended uses: management of insomnia, anxiety, and agitation |
| |
General cautions: regular use can lead to tolerance, addiction, depression, and cognitive impairment; paradoxic agitation occurs in about 10% of patients treated with benzodiazepines; infrequent, low doses of agents with a short half-life are least problematic. |
| |
Lorazepam (Ativan), oxazepam (Serax), temazepam (Restoril), zolpidem (Ambien), triazolam (Halcion) |
Dosage: varies by agent |
See general cautions. |
| Nonbenzodiazepines |
| |
Buspirone (BuSpar) |
Initial dosage: 5 mg twice daily; maximum: 20 mg three times daily |
Comments: useful only in patients with mild to moderate agitation; may take 2 to 4 weeks to become effective |
|
Antidepressant drugs
|
| |
Recommended uses: see comments on specific agents. |
| |
General cautions: selection of an antidepressant is usually based on previous treatment response, tolerance, and the advantage of potential side effects (e.g., sedation versus activation); a full therapeutic trial requires at least 4 to 8 weeks; as a rule, dosage is increased using increments of initial dose every 5 to 7 days until therapeutic benefits or significant side effects become apparent; after 9 months, dosage reduction is used to reassess the need to medicate; discontinuing an antidepressant over 10 to 14 days limits withdrawal symptoms. NOTE: Patients with depression and psychosis require concomitant antipsychotic medication. |
| Tricyclic antidepressant agents |
| |
Desipramine (Norpramin) |
Initial dosage: 10 to 25 mg in the morning; maximum: 150 mg in the morning |
Comments: tends to be activating (i.e., reduces apathy); lower risk for cardiotoxic, hypotensive, and anticholinergiceffects; may cause tachycardia; blood levels may be helpful. |
| |
Nortriptyline (Pamelor) |
Initial dosage: 10 mg at bedtime; anticipated dosage range: 10 to 40 mg per day (given twice daily) |
Comments: tolerance profile is similar to that for desipramine, but nortriptyline tends to be more sedating; may be useful in patients with agitated depression and insomnia; therapeutic blood level "window" of 50 to 150 ng per mL (190 to 570 nmol per L) |
| Heterocyclic and noncyclic antidepressant agents |
| |
Nefazodone (Serzone) |
Initial dosage: 50 mg twice daily; maximum: 150 to 300 mg twice daily |
Comments: effective, especially in patients with associatedanxiety; reduce dose of coadministered alprazolam (Xanax) or triazolam by 50%; monitor for hepatotoxicity. |
| |
Bupropion (Wellbutrin) |
Initial dosage: 37.5 mg every morning, then increase by 37.5 every 3 days; maximum: 150 mg twice daily |
Comments: activating; possible rapid improvement of energylevel; should not be used in agitated patients and those with seizure disorders; to minimize risk of insomnia, give second dose before 3 p.m. |
| |
Mirtazapine (Remeron) |
Initial dosage: 7.5 mg at bedtime; maximum: 30 mg at bedtime |
Comments: potent and well tolerated; promotes sleep, appetite, and weight gain |